Evidence map›Paper›PMID 29872621›Full record

ReviewActa pharmaceutica Sinica. B2018

Biomacromolecules as carriers in drug delivery and tissue engineering.

Yujie Zhang, Tao Sun, Chen Jiang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Acute pancreatitis: mechanisms and therapeutic approaches.Signal transduction and targeted therapy · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yujie ZhangKey Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, China.
Tao SunKey Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, China.
Chen JiangKey Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural biomacromolecules have attracted increased attention as carriers in biomedicine in recent years because of their inherent biochemical and biophysical properties including renewability, nontoxicity, biocompatibility, biodegradability, long blood circulation time and targeting ability. Recent advances in our understanding of the biological functions of natural-origin biomacromolecules and the progress in the study of biological drug carriers indicate that such carriers may have advantages over synthetic material-based carriers in terms of half-life, stability, safety and ease of manufacture. In this review, we give a brief introduction to the biochemical properties of the widely used biomacromolecule-based carriers such as albumin, lipoproteins and polysaccharides. Then examples from the clinic and in recent laboratory development are summarized. Finally the current challenges and future prospects of present biological carriers are discussed.

Indexed as

ABD, albumin binding domainACM, aclacinomycinACS, absorbable collagen spongeADH, adipic dihydrazideART, artemisininASF, Antheraea mylitta silk fibroinATRA, all-trans retinoic acidATS, artesunateBCEC, brain capillary endothelial cellsBiomacromoleculeBMP-2, bone morphogenetic protein-2BSA, bovine serum albuminBSF, Bombyx mori silk fibroinCC-HAM, core-crosslinked polymeric micelle based hyaluronic acidCD/BP, cyclodextrin–bisphosphonate complexesCD, cyclodextrinCD-g-CS, chitosan grafted with β-cyclodextrinCD-NPs, amphiphilic MMA–tBA β-CD star copolymers that are capable of forming nanoparticlesCIA, collagen-induced arthritisCM, collagen matricesCMD-ChNP, carboxylmethyl dextran chitosan nanoparticleDHA, dihydroartesunateDOXO-EMCH, (6-maleimidocaproyl)hydrazone derivative of doxorubicinDOX–TRF, doxorubincin–transferrin conjugateDrug deliveryDTX-HPLGA, HA coated PLGA nanoparticulate docetaxelECM, extracellular matrixEMT, epithelial mesenchymal transitionEPR, enhanced permeability and retentionFcRn, neonatal Fc receptorGAG, glycosaminoglycanGC-DOX, glycol–chitosan–doxorubicin conjugateGd, gadoliniumGDNF, glial-derived neurotrophic factorGO, grapheme oxideGSH, glutathioneHA-CA, catechol-modified hyaluronic acidHA, hyaluronic acidHCF, heparin-conjugated fibrinHDL, high density lipoproteinHEK, human embryonic kidneyHSA, human serum albuminIDL, intermediate density lipoproteinINF, interferonLDL, low density lipoproteinLDLR, low density lipoprotein receptorLDV, leucine–aspartic acid–valineLMWH, low molecular weight heparinMSA, mouse serum albuminMTX–HSA, methotrexate–albumin conjugateNIR, near-infraredNSCLC, non-small cell lung cancerOP-Gel-NS, oxidized pectin-gelatin-nanosliverpDNA, plasmid DNAPEC, polyelectrolytePolysaccharideProteinPTX, paclitaxelRES, reticuloendothelial systemRGD, Arg–Gly–Asp peptiderHDL, recombinant HDLrhEGF-2/HA, recombinant human fibroblast growth factor type 2 in a hyaluronic acid carrierSF-CSNP, silk fibroin modified chitosan nanoparticleSFNP, silk fibroin nanoparticleSF, silk fibroinSPARC, secreted protein acidic and rich in cysteineTfR, transferrin receptorTf, transferrinTissue engineeringTRAIL, tumor-necrosis factor-related apoptosis-inducing ligandVEGF, vascular endothelial growth factorVLDL, very low density lipoprotein

Identifiers

PMID29872621
PMCPMC5985630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.